Black Diamond Therapeutics Inc logo

BDTX

Black Diamond Therapeutics Inc

$3.77

Earnings Summary

Revenue
$0Mn
Net Profits
$-25.51Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Black Diamond Therapeutics Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Black Diamond Therapeutics Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Black Diamond Therapeutics Inc’s net profit jumped 15.82% since last year same period to $-25.51Mn in the Q1 2022. On a quarterly growth basis, Black Diamond Therapeutics Inc has generated -125.61% fall in its net profits since last 3-months.

Net Profit Margins:

Black Diamond Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Black Diamond Therapeutics Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Black Diamond Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.68
EPS Estimate Current Year
-0.68

Highlights

EPS Estimate Current Quarter:

Black Diamond Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.68 - a 9.33% jump from last quarter’s estimates.

EPS Estimate Current Year:

Black Diamond Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.68.

Key Ratios

Key ratios of the Black Diamond Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.7
Return on Assets (ROA)
-0.28
Return on Equity (ROE)
-0.54
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Black Diamond Therapeutics Inc’s earning per share (EPS) jumped 16.67% since last year same period to -0.7 in the Q1 2022. This indicates that the Black Diamond Therapeutics Inc has generated 16.67% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Black Diamond Therapeutics Inc’s return on assets (ROA) stands at -0.28.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Black Diamond Therapeutics Inc’s return on equity (ROE) stands at -0.54.

Dividend Per Share (DPS):

Black Diamond Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-11
-0.75
-0.7
6.67%

Company Information

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company's proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine.

Organisation
Black Diamond Therapeutics Inc
Employees
73
Industry
Health Technology